Why the study?
Does clozapine treatment cause significant cardiac morbidity or mortality in inpatients with treatment-refractory schizophrenia?
Population
39 inpatients with treatment-refractory schizophrenia referred for cardiology opinion
Comparison
Clozapine vs Other antipsychotic medication
Design
Cohort
Follow-up
4 months for serial echocardiograms; up to 11 years for…
Authors
Loading...
Supports continued clozapine use under routine monitoring; leaves open the need for larger prospective studies on cardiac outcomes.
Does clozapine treatment cause significant cardiac morbidity or mortality in inpatients with treatment-refractory schizophrenia?
Clozapine treatment in patients with treatment-refractory schizophrenia is not associated with significant cardiac morbidity or mortality, suggesting that cardiac concerns may not warrant routine discontinuation.
Joy et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: